JP3272891B2 - Bath additive - Google Patents
Bath additiveInfo
- Publication number
- JP3272891B2 JP3272891B2 JP31256194A JP31256194A JP3272891B2 JP 3272891 B2 JP3272891 B2 JP 3272891B2 JP 31256194 A JP31256194 A JP 31256194A JP 31256194 A JP31256194 A JP 31256194A JP 3272891 B2 JP3272891 B2 JP 3272891B2
- Authority
- JP
- Japan
- Prior art keywords
- sodium
- oil
- collagen
- procollagenase
- bath
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000654 additive Substances 0.000 title claims description 4
- 230000000996 additive effect Effects 0.000 title claims description 4
- -1 alkyl silicate Chemical compound 0.000 claims description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 17
- 235000010323 ascorbic acid Nutrition 0.000 claims description 8
- 229960005070 ascorbic acid Drugs 0.000 claims description 8
- 239000011668 ascorbic acid Substances 0.000 claims description 8
- 239000013040 bath agent Substances 0.000 claims description 6
- 108010029690 procollagenase Proteins 0.000 description 22
- 102000008186 Collagen Human genes 0.000 description 19
- 108010035532 Collagen Proteins 0.000 description 19
- 229920001436 collagen Polymers 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000003788 bath preparation Substances 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 108060005980 Collagenase Proteins 0.000 description 12
- 102000029816 Collagenase Human genes 0.000 description 12
- 229960002424 collagenase Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- JDAIJCNBFIWLJJ-UHFFFAOYSA-N ethoxy-hydroxy-oxosilane Chemical compound CCO[Si](O)=O JDAIJCNBFIWLJJ-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000007306 turnover Effects 0.000 description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000003287 bathing Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 239000007758 minimum essential medium Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- FKKAGFLIPSSCHT-UHFFFAOYSA-N 1-dodecoxydodecane;sulfuric acid Chemical compound OS(O)(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC FKKAGFLIPSSCHT-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 240000005809 Prunus persica Species 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000010666 rose oil Substances 0.000 description 2
- 235000019719 rose oil Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 241000736892 Thujopsis dolabrata Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- FAYYUXPSKDFLEC-UHFFFAOYSA-L calcium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [Ca+2].[O-]S([O-])(=O)=S FAYYUXPSKDFLEC-UHFFFAOYSA-L 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000010627 cedar oil Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 239000001071 citrus reticulata blanco var. mandarin Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000007691 collagen metabolic process Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000010656 jasmine oil Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- DPLVEEXVKBWGHE-UHFFFAOYSA-N potassium sulfide Chemical compound [S-2].[K+].[K+] DPLVEEXVKBWGHE-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229910000031 sodium sesquicarbonate Inorganic materials 0.000 description 1
- 235000018341 sodium sesquicarbonate Nutrition 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 235000001508 sulfur Nutrition 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LFQCEHFDDXELDD-UHFFFAOYSA-N tetramethyl orthosilicate Chemical compound CO[Si](OC)(OC)OC LFQCEHFDDXELDD-UHFFFAOYSA-N 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- FXSGDOZPBLGOIN-UHFFFAOYSA-N trihydroxy(methoxy)silane Chemical compound CO[Si](O)(O)O FXSGDOZPBLGOIN-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は、老化に伴うコラーゲン
の代謝回転速度低下の改善効果を有し、美肌効果に優
れ、かつ商品的に凝集性の無い入浴剤に係り、さらに詳
しくは細胞のプロコラゲナーゼ産生を促進するケイ酸ア
ルキルエステルまたはそれとコラーゲン合成を促進する
アスコルビン酸またはその誘導体とを含有することを特
徴とする入浴剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a bath preparation which has an effect of improving the rate of turnover of collagen due to aging, has an excellent skin effect, and has no commercial cohesiveness. The present invention relates to a bath preparation characterized by containing a silicic acid alkyl ester which promotes procollagenase production or ascorbic acid or a derivative thereof which promotes collagen synthesis.
【0002】[0002]
【従来の技術】皮膚にはコラーゲンが乾燥重量比で70
%含まれており、皮膚に物理的特性を与えると共に、細
胞の増殖、分化、移動などの生理的な影響も与えてい
る。このコラーゲンは、老化に伴い代謝回転速度が生理
的に低下することが知られている(現代化学、12月
号、36頁、1990年参照)。2. Description of the Related Art Collagen is 70% by dry weight in the skin.
It has physical properties to the skin as well as physiological effects such as cell proliferation, differentiation and migration. It is known that the turnover rate of this collagen is physiologically lowered with aging (see Hyundai Kagaku, December, p. 36, 1990).
【0003】老化に伴ってコラーゲン代謝回転速度が低
下すると、コラーゲン分子の寿命が長くなり、分子間架
橋の割合が増すと共に、コラゲナーゼ分解に抵抗性を示
すようになる(Aging of the Skin 、121 頁、1989年、
Raven Press 、New York)。その結果、一定量のコラー
ゲンを分解するために必要とされるコラゲナーゼの量が
増加し、ますます代謝回転速度が低下するという悪循環
を引き起こすことになる。[0003] When the rate of collagen turnover decreases with aging, the life span of collagen molecules increases, the rate of intermolecular cross-linking increases, and the collagen molecules become resistant to collagenase degradation (Aging of the Skin, page 121). , 1989,
Raven Press, New York). As a result, the amount of collagenase required to degrade a certain amount of collagen increases, causing a vicious cycle of increasingly slowing turnover.
【0004】この悪循環の結果、皮膚の柔軟性、弾力性
の低下や皺の増加が起こることが示唆されている。[0004] It has been suggested that as a result of this vicious cycle, skin softness and elasticity are reduced and wrinkles are increased.
【0005】ところで、コラゲナーゼは、結合組織中の
間質型コラーゲン(I型、II型、およびIII 型コラーゲ
ン)を分解する際の律速酵素であり、コラーゲンの代謝
に重要な役割を果たしている。コラゲナーゼは、前駆体
であるプロコラゲナーゼとして細胞より分泌され、生体
内ではその後プラスミンやストロムライシン等のタンパ
ク分解酵素によってコラゲナーゼに活性化される(Bioch
emical Journal、166巻、21頁、1977年および Proceedi
ngs of the National Academy of Sciences of the U.
S.A.、86巻、2632頁、1989年参照)と考えられている。[0005] Collagenase is a rate-limiting enzyme in decomposing interstitial collagen (type I, type II, and type III collagen) in connective tissue, and plays an important role in collagen metabolism. Collagenase is secreted from cells as a precursor, procollagenase, and then activated in vivo by collagenase by proteolytic enzymes such as plasmin and stromlysin (Bioch.
emical Journal, 166, 21 pages, 1977 and Proceedi
ngs of the National Academy of Sciences of the U.
SA, 86, 2632, 1989).
【0006】以上のことから、老化に伴うコラーゲンの
代謝回転速度低下の改善のためには、プロコラゲナーゼ
産生促進物質が有効と考えられる。[0006] From the above, it is considered that a procollagenase production promoting substance is effective for improving the decrease in collagen turnover rate due to aging.
【0007】さらに、コラーゲンの代謝回転速度低下の
改善のためには、コラゲナーゼによる分解促進のみでな
く、同時にコラーゲン合成を促進するとより有効であ
り、プロコラゲナーゼ産生促進物質とともにコラーゲン
合成促進物質を共用することが有効と考えられる。Further, in order to improve the decrease in the turnover rate of collagen, it is more effective not only to promote the degradation by collagenase but also to promote the synthesis of collagen at the same time, and to use the collagen synthesis promoting substance together with the procollagenase production promoting substance. Is considered effective.
【0008】細胞のプロコラゲナーゼ産生能を増強する
ことを可能とする物質として、これまで、インターロイ
キン1、腫瘍壊死因子(TNF)、表皮成長因子(EG
F)、血小板由来成長因子(PDGF)等のサイトカイ
ンおよびホルボールエステル等が知られている。しかし
これらのサイトカイン類は高価であり、製造コストが高
くなる。また、ホルボールエステルは発癌プロモーター
物質であってその使用は安全と言いがたい。[0008] Interleukin 1, tumor necrosis factor (TNF), epidermal growth factor (EG) have been known as substances capable of enhancing the procollagenase-producing ability of cells.
F), cytokines such as platelet-derived growth factor (PDGF) and phorbol esters are known. However, these cytokines are expensive and the production cost is high. In addition, phorbol ester is a tumor promoter and its use is hard to say safe.
【0009】一方、従来より様々な入浴剤が開発されて
いるが、前記の様な生理活性物質を配合しようとした場
合、一般に使用される所の入浴剤成分と混合すると成分
同士が凝集してしまうといったことが生じ、外観を悪く
し、また浴湯に分散しにくくなるといった欠点があり、
商品価値を著しく低下させてしまうといったことがあ
る。[0009] On the other hand, various bathing agents have been conventionally developed, but when the above-mentioned physiologically active substances are to be blended, when they are mixed with a bathing agent component which is generally used, the components coagulate. There are drawbacks, such as the appearance and bad appearance, and it is difficult to disperse in bath water.
In some cases, the product value is significantly reduced.
【0010】[0010]
【発明が解決しようとする課題】したがって、本発明の
目的とするところは、老化に伴うコラーゲンの代謝回転
速度低下の改善効果を有し、美肌効果に優れ、かつ商品
的に凝集性の無い入浴剤を提供することにある。SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to provide a bath which has an effect of improving a decrease in the turnover rate of collagen due to aging, is excellent in beautiful skin effect, and has no commercial cohesiveness. To provide an agent.
【0011】[0011]
【課題を解決するための手段】上述の目的は、細胞のプ
ロコラゲナーゼ産生を促進する、オルガノアルコキシシ
ランを除くケイ酸アルキルエステル、またはオルガノア
ルコキシシランを除くケイ酸アルキルエステルとコラー
ゲン合成を促進するアスコルビン酸またはその誘導体と
を含有することを特徴とする入浴剤によって達成され
る。SUMMARY OF THE INVENTION An object of the present invention is to provide an organoalkoxy compound that promotes the production of procollagenase in cells.
Silicic acid alkyl ester excluding orchid or organoa
This is achieved by a bath additive characterized by containing an alkyl silicate ester excluding lucoxysilane and ascorbic acid or a derivative thereof that promotes collagen synthesis.
【0012】本発明に用いられるプロコラゲナーゼ産生
促進物質としてのケイ酸アルキルエステルとしては、オ
ルガノアルコキシシランを除くケイ酸アルキルエステル
であり、具体的には、たとえばケイ酸メチルエステル、
ケイ酸エチルエステル、メタケイ酸メチルエステル、メ
タケイ酸エチルエステル、メタケイ酸プロピルエステ
ル、オルトケイ酸メチルエステル、オルトケイ酸エチル
エステル等が挙げられる。[0012] As silicic acid alkyl ester as procollagenase production promoting substance for use in the present invention, O
Silicic acid alkyl esters excluding luganoalkoxysilane
Specifically , for example, silicic acid methyl ester,
Examples include ethyl silicate, methyl meta-silicate, ethyl meta-silicate, propyl meta-silicate, methyl ortho-silicate, and ethyl ortho-silicate.
【0013】本発明に用いられるケイ酸アルキルエステ
ルの含有量は、入浴剤の総量を基準として0.1〜20
重量%が好ましく、さらに好ましくは1〜15重量%で
ある。The content of the alkyl silicate used in the present invention is 0.1 to 20 based on the total amount of the bath agent.
% By weight, more preferably 1 to 15% by weight.
【0014】本発明に用いられるコラーゲン合成促進物
質としてのアスコルビン酸またはその誘導体としては、
アスコルビン酸とその塩(ナトリウム塩、マグネシウム
塩等)、アスコルビン酸リン酸エステルおよび硫酸エス
テルとその塩(マグネシウム塩等)、ステアリン酸エス
テル、ジパルミチン酸エステルおよびモノパルミチン酸
エステル等が挙げられる。Ascorbic acid or a derivative thereof as a collagen synthesis promoter used in the present invention includes:
Ascorbic acid and its salts ( such as sodium salts and magnesium salts), ascorbic acid phosphates and sulfates and their salts ( such as magnesium salts), stearates, dipalmitates and monopalmitates.
【0015】本発明に用いられるアスコルビン酸または
その誘導体の含有量は、入浴剤総量を100として0.
001〜10重量%が好ましく、さらに好ましくは0.
01〜3重量%である。The content of ascorbic acid or a derivative thereof used in the present invention is 0.1% based on the total amount of the bathing agent as 100.
It is preferably from 001 to 10% by weight, more preferably from 0.1 to 10% by weight.
01 to 3% by weight.
【0016】本発明における有効成分のケイ酸アルキル
エステルとともに配合する他の入浴用剤成分としては、
通常使用されるいずれのものも使用出来るが、効能、効
果に応じ以下の物質から適宜選択出来る。The other bathing agent components to be blended with the active ingredient alkyl silicate in the present invention include:
Any of the commonly used substances can be used, but can be appropriately selected from the following substances according to the efficacy and effect.
【0017】1)無機塩類 塩化ナトリウム、炭酸水素ナトリウム、炭酸ナトリウ
ム、ホウ酸、ほう砂、硫酸ナトリウム、硫化ナトリウ
ム、硫化カリウム、硝酸ナトリウム、硝酸カルシウム、
硫酸アンモニウム、チオ硫酸ナトリウム、リン酸水素カ
ルシウム、塩化カリウム、塩化アンモニウム、リン酸ナ
トリウム、次亜硫酸ナトリウム、チオ硫酸カルシウム、
硫黄、尿素、セスキ炭酸ナトリウム、硫酸マグネシウム
等。1) Inorganic salts: sodium chloride, sodium hydrogen carbonate, sodium carbonate, boric acid, borax, sodium sulfate, sodium sulfide, potassium sulfide, sodium nitrate, calcium nitrate,
Ammonium sulfate, sodium thiosulfate, calcium hydrogen phosphate, potassium chloride, ammonium chloride, sodium phosphate, sodium hyposulfite, calcium thiosulfate,
Sulfur, urea, sodium sesquicarbonate, magnesium sulfate, etc.
【0018】2)有機酸類 安息香酸、クエン酸、フマル酸、酒石酸、リンゴ酸、サ
リチル酸等。2) Organic acids Benzoic acid, citric acid, fumaric acid, tartaric acid, malic acid, salicylic acid and the like.
【0019】3)油脂類 オリーブ油、大豆油、アーモンド油、ひまし油、やし
油、パーム油、タートル油、ヌカ油、ホホバ油、ミンク
油、卵黄油、スクワラン、アボガド油、ラノリン、流動
パラフィン、白色ワセリン、DHA、EPA等。3) Oils and fats Olive oil, soybean oil, almond oil, castor oil, coconut oil, palm oil, turtle oil, nuka oil, jojoba oil, mink oil, egg yolk oil, squalane, avocado oil, lanolin, liquid paraffin, white Vaseline, DHA, EPA and the like.
【0020】4)粘結剤類 カルボキシメチルセルロースナトリウム、メチルセルロ
ース、ナトリウム塩、カゼイン、ぺクチン、デンプン、
アルギン酸ナトリウム、ポリビニルアルコール、ポリビ
ニルピロリドン、ローカストビーンガム、カラギナン、
寒天、カーボポール等。4) Binders Sodium carboxymethylcellulose, methylcellulose, sodium salt, casein, pectin, starch,
Sodium alginate, polyvinyl alcohol, polyvinylpyrrolidone, locust bean gum, carrageenan,
Agar, carbopol, etc.
【0021】5)多価アルコール類、保湿剤 グリセリン、プロピレングリコール、ソルビトール、ポ
リエチレングリコール、1,3−ブチレングリコール、
ビタミンCおよびその誘導体、加水分解シルク、コラー
ゲン、コンドロイチンおよびその蛋白複合体、グリチル
リチンおよびその誘導体等。5) Polyhydric alcohols, humectants glycerin, propylene glycol, sorbitol, polyethylene glycol, 1,3-butylene glycol,
Vitamin C and its derivatives, hydrolyzed silk, collagen, chondroitin and its protein complexes, glycyrrhizin and its derivatives, and the like.
【0022】6)界面活性剤 ラウリル硫酸ナトリウム、ポリオキシエチレンラウリル
エーテル硫酸ナトリウム、ラウリン酸ジエタノールアミ
ド、グリセリンモノステアレート、ポリエチレングリコ
ールモノステアレート、ポリオキシエチレングリセリル
モノステアレート、ソルビタンモノラウレート、ポリオ
キシエチレンソルビタンモノオレエート、ポリオキシエ
チレンセチルエーテル、ポリオキシエチレン硬化ヒマシ
油、脂肪酸セッケン、N−アシルグルタミン酸塩等。6) Surfactant Sodium lauryl sulfate, sodium polyoxyethylene lauryl ether sulfate, diethanolamide laurate, glycerin monostearate, polyethylene glycol monostearate, polyoxyethylene glyceryl monostearate, sorbitan monolaurate, poly Oxyethylene sorbitan monooleate, polyoxyethylene cetyl ether, polyoxyethylene hydrogenated castor oil, fatty acid soap, N-acyl glutamate and the like.
【0023】7)香料類 ラベンダー油、ジャスミン油、ローズ油、レモン油、オ
レンジ油、ハッカ油、タイム油、ショウブ油、ウイキョ
ウ油、スギ油、ヒバ油、ヒノキ油、バラ油、ユーカリ
油、カンファー、ペパーミント油、スペアミント油、ゲ
ラニオール、ミカン油油、トウヒ、シトロネロール等の
天然及び合成香料等。7) Flavors Lavender oil, jasmine oil, rose oil, lemon oil, orange oil, peppermint oil, thyme oil, shobu oil, fennel oil, cedar oil, hiba oil, hinoki oil, rose oil, eucalyptus oil, camphor And natural and synthetic flavors such as peppermint oil, spearmint oil, geraniol, mandarin oil, spruce and citronellol.
【0024】さらに、本発明の浴用剤組成物は、上記の
もの以外にも、必要に応じてその他の成分として、生薬
類、殺菌剤、ビタミン類、および化粧品用タール系色素
等を適宜配合出来る。Further, the bath composition of the present invention may optionally contain, as necessary, other ingredients other than the above, such as crude drugs, bactericides, vitamins, and tar dyes for cosmetics. .
【0025】本発明の入浴剤を使用する場合、老化に伴
いコラーゲン代謝回転の低下した皮膚に対しては、 1〜
200mg/lの濃度で一日あたり10〜30分入浴するのが適当
である。When the bath preparation of the present invention is used, the skin whose collagen turnover has been reduced due to aging is 1 to
It is appropriate to bathe at a concentration of 200 mg / l for 10 to 30 minutes per day.
【0026】[0026]
【実施例】以下、試験例、実施例および比較例を挙げて
本発明を詳細に説明する。ただし、本発明は例中に記さ
れた原料、配合比に限定されるものではない。なお、試
験例中に用いた語句の定義を記載する。The present invention will be described below in detail with reference to Test Examples, Examples and Comparative Examples. However, the present invention is not limited to the raw materials and compounding ratios described in the examples. In addition, the definition of the phrase used in the test example is described.
【0027】MEM培地:最少必須培地10−101
(大日本製薬社製)1袋に精製水1l加え、それぞれ終
濃度0. 1重量%ラクトアルブミン酵素水解物(シグマ
社製)、1容量%非必須アミノ酸、1mMピルビン酸ナト
リウム(以上いずれも大日本製薬社製)、0. 12重量
%炭酸水素ナトリウムおよび50mg/lストレプトマイシ
ンを添加して調製する。 MEM medium : Minimum essential medium 10-101
(Dai Nippon Pharmaceutical Co., Ltd.) Add 1 liter of purified water to one bag, each with a final concentration of 0.1% by weight lactalbumin enzyme hydrolyzate (Sigma), 1% by volume non-essential amino acid, 1 mM sodium pyruvate (all above are large) It is prepared by adding 0.12% by weight of sodium hydrogen carbonate and 50 mg / l of streptomycin.
【0028】FBS:牛胎仔血清 FBS : fetal calf serum
【0029】測定用緩衝液:0.2MNaCl、5mMCaCl2、0.05
容量%Brij-35 を含有する50mMトリス(ヒドロキシメチ
ル)アミノメタン(以後単にトリスと略記する)水溶液
を塩酸にて室温でpH7.5 に調整した緩衝液。 Measurement buffer : 0.2 M NaCl, 5 mM CaCl 2 , 0.05
A buffer in which a 50 mM aqueous solution of Tris (hydroxymethyl) aminomethane (hereinafter simply referred to as Tris) containing volume% Brij-35 is adjusted to pH 7.5 with hydrochloric acid at room temperature.
【0030】プロコラゲナーゼ産生量:本実験では、プ
ロコラゲナーゼ産生量は、トリプシンで活性化して得ら
れるコラゲナーゼ活性として定量した。 Procollagenase production : In this experiment, procollagenase production was quantified as collagenase activity obtained by activation with trypsin.
【0031】試験例−1 本実験で用いた細胞では、産生されるコラゲナーゼはそ
のままでは活性をもたないプロコラゲナーゼとして回収
されるので、プロコラゲナーゼ産生量は、トリプシンで
活性化して得られるコラゲナーゼ活性として定量した。Test Example 1 In the cells used in the present experiment, the produced collagenase is recovered as a procollagenase having no activity as it is, and thus the amount of procollagenase produced is determined by the collagenase activity obtained by activating with trypsin. As quantified.
【0032】正常ヒト線維芽細胞株〔白人女性の皮膚よ
り採取されたDetroit-551(ATCC CCL110) 〕を10容量
%ウシ胎仔血清(以下FBSと略記)を含むMEM培地
にて1x105 個/mlに調製し、6穴プレートに2mlず
つ播種して、5%炭酸ガス、飽和水蒸気下、37℃で培
養した。A normal human fibroblast cell line [Detroit-551 (ATCC CCL110) collected from the skin of a Caucasian woman] was cultured at 1 × 10 5 cells / ml in a MEM medium containing 10% by volume of fetal bovine serum (hereinafter abbreviated as FBS). And 2 ml of each was seeded on a 6-well plate, and cultured at 37 ° C. under 5% carbon dioxide gas and saturated steam.
【0033】なお、MEM培地は、最少必須培地10−
101(大日本製薬社製)に、それぞれ終濃度0.1重
量%ラクトアルブミン酵素水解物(シグマ社製)、1容
量%非必須アミノ酸、1mMピルビン酸ナトリウム(以上
いずれも大日本製薬社製)、0.12重量%炭酸水素ナ
トリウムおよび50mg/lストレプトマイシンを添加して
調製した。The MEM medium is the minimum essential medium 10-
101 (manufactured by Dainippon Pharmaceutical Co., Ltd.), a final concentration of 0.1% by weight lactalbumin enzyme hydrolyzate (manufactured by Sigma), 1% by volume non-essential amino acid, 1 mM sodium pyruvate (all are manufactured by Dainippon Pharmaceutical Co., Ltd.) , 0.12% by weight sodium bicarbonate and 50 mg / l streptomycin.
【0034】後記実施例1の10mMメタケイ酸エチルエ
ステル溶液を、0.6 容量%FBSを添加したMEM培地
で希釈して各濃度の添加溶液とした。The 10 mM ethyl metasilicate solution of Example 1 described later was diluted with MEM medium supplemented with 0.6% by volume of FBS to obtain additive solutions of various concentrations.
【0035】24時間後培養液を吸引除去し、終濃度
0.6容量%FBSを添加したMEM培地で細胞を2回
洗浄した後、各添加溶液2mlを加え、7日間培養して培
養上清を得た。After 24 hours, the culture medium was removed by suction, and the cells were washed twice with MEM medium supplemented with a final concentration of 0.6% by volume of FBS. I got
【0036】得られた培養上清250μlに10mMトリ
ス塩酸緩衝液(4℃でpH7.8に調整、1mM塩化カルシ
ウム、0.05容量%Brij-35 を含む)を1.75ml加
え、同緩衝液で平衡化した CM-セファロースCL-6B
TM(ファルマシア社製、ベッド容量0.5ml)に供し
た。To 250 μl of the obtained culture supernatant, 1.75 ml of 10 mM Tris-HCl buffer (adjusted to pH 7.8 at 4 ° C. and containing 1 mM calcium chloride and 0.05% by volume Brij-35) was added, and the same buffer was added. CM-Sepharose CL-6B equilibrated with
TM (Pharmacia, bed capacity 0.5 ml).
【0037】つぎに、125mM食塩を含む同緩衝液0.
5mlにてインヒビターを除去(計4回、総量2ml)し、
500mM食塩を含む同緩衝液0.5mlにてプロコラゲナ
ーゼを回収(計4回、総量2ml)し、試験液とした。Next, the same buffer solution containing 125 mM saline was added.
Inhibitor was removed with 5 ml (total 4 times, total volume 2 ml),
Procollagenase was recovered with 0.5 ml of the same buffer containing 500 mM salt (total 4 times, 2 ml in total) to prepare a test solution.
【0038】さらに、試験液50μl にトリプシン溶液
(シグマ社製、Type 12 を測定用緩衝液にて濃度1 mg/m
l に調製)20μl を添加し、35℃にて5分間インキュベ
ートした後、ダイズトリプシンインヒビター溶液(メル
ク社製 No.24020を測定用緩衝液にて濃度3 mg/ml に調
製)30μl を添加してトリプシンを失活させ、コラゲナ
ーゼ溶液を得た。Further, 50 μl of the test solution was mixed with a trypsin solution (Type 12 manufactured by Sigma) at a concentration of 1 mg / m 2 in a measuring buffer.
20 μl) and incubated at 35 ° C. for 5 minutes, and then add 30 μl of soybean trypsin inhibitor solution (Merck's No. 24020 to a concentration of 3 mg / ml in a measurement buffer). Trypsin was inactivated to obtain a collagenase solution.
【0039】フルオレッセンイソチオシアネートで標識
されたI型コラーゲン(濃度1mg/ml のFITC- コラーゲ
ン酢酸溶液、コスモバイオ社製)を基質溶液として用
い、永井等の方法(炎症、4巻、2号、123頁、1984
年参照)に準じて上記コラゲナーゼの活性(単位/ml)
を測定した。そして、上記のトリプシン処理によりプロ
コラゲナーゼから生じるコラゲナーゼが、35℃にて1 分
間当り1 μg のI型コラーゲン(FITC- コラーゲン)を
分解する量をプロコラゲナーゼの1単位とし、プロコラ
ゲナーゼ産生量(単位/培養液ml)を求めた(この値を
Xとする)。Using type I collagen labeled with fluorescein isothiocyanate (FITC-collagen acetate solution at a concentration of 1 mg / ml, manufactured by Cosmo Bio Inc.) as a substrate solution, the method of Nagai et al. (Inflammation, Vol. 4, No. 2, 123 pages, 1984
Activity of the above collagenase (unit / ml)
Was measured. The amount of collagenase generated from procollagenase by the above-described trypsin treatment to decompose 1 μg of type I collagen (FITC-collagen) per minute at 35 ° C. is defined as one unit of procollagenase. / Ml of culture solution) (this value is defined as X).
【0040】一方、対照試験としてメタケイ酸エチルエ
ステルの代わりに精製水を加え、上記と同様の操作によ
りメタケイ酸エチルエステルを添加しない場合のプロコ
ラゲナーゼ産生量(単位/培養液ml)を求めた(この値
をYとする)。On the other hand, as a control test, purified water was added in place of metasilicate ethyl ester, and the amount of procollagenase production (unit / ml of culture solution) without addition of metasilicate ethyl ester was determined in the same manner as described above. This value is Y).
【0041】ついで、これらの値から下式によりプロコ
ラゲナーゼ産生促進率を算出した。Next, the procollagenase production promotion rate was calculated from these values according to the following equation.
【0042】 プロコラゲナーゼ産生促進率=(X/Y)Procollagenase production promotion rate = (X / Y)
【0043】得られた培養上清中のプロコラゲナーゼ量
を定量した結果を表1に示す。The results of quantifying the amount of procollagenase in the obtained culture supernatant are shown in Table 1.
【0044】[0044]
【表1】 [Table 1]
【0045】表1に記載の通り、対照(無添加)では5
6.5±3.6単位/ml(平均値±標準誤差、n=3)
に対し、メタケイ酸エチルエステル添加では用量依存的
に有意にプロコラゲナーゼの産生を促進した。As shown in Table 1, in the control (no addition), 5
6.5 ± 3.6 units / ml (mean ± standard error, n = 3)
In contrast, the addition of ethyl metasilicate significantly promoted the production of procollagenase in a dose-dependent manner.
【0046】試験例−2 試験例−1と同様に、後記実施例2、3、4のケイ酸ア
ルキルエステル溶液を正常ヒト線維芽細胞に添加し、プ
ロコラゲナーゼ産生を調べた。Test Example 2 Similarly to Test Example 1, the silicate alkyl ester solutions of Examples 2, 3, and 4 described below were added to normal human fibroblasts, and the production of procollagenase was examined.
【0047】得られた培養上清中のプロコラゲナーゼ量
を定量した結果を表2に示す。Table 2 shows the results obtained by quantifying the amount of procollagenase in the obtained culture supernatant.
【0048】[0048]
【表2】 [Table 2]
【0049】表2に記載した通り、対照(無添加)では
56.5±6.2単位/ml(平均値±標準誤差、n=
3)に対し、ケイ酸エチルエステル、メタケイ酸プロピ
ルエステルおよびオルトケイ酸エチルエステルは有意に
プロコラゲナーゼの産生を促進した。As described in Table 2, in the control (no addition), 56.5 ± 6.2 units / ml (mean ± standard error, n =
In contrast to 3), ethyl silicate, propyl metasilicate and ethyl orthosilicate significantly promoted the production of procollagenase.
【0050】試験例−3 メタケイ酸エチルエステルを含む入浴剤について、実際
に以下のように入浴効果を調べた。Test Example 3 The bathing effect of a bathing agent containing ethyl metasilicate was actually examined as follows.
【0051】後記実施例5の入浴剤50g とその比較例
1の入浴剤50g 、または後記実施例6の入浴剤50g
とその比較例2の入浴剤50.0g を、それぞれ41℃
のお湯180lに投入した。被験者10名ずつ、右足を
実施例5または6のお湯に、左足を比較例2または3の
お湯に、1日3回(朝、昼、夜)それぞれ5分、10日
間部分浴させた。10日後前足側部皮膚表面の皮溝状態
を、拡大ビデオカメラで観察し、以下の基準で点数をつ
けた。さらに、アンケートによる評価も以下の基準で行
った。50 g of the bath agent of Example 5 described later and 50 g of the bath agent of Comparative Example 1 or 50 g of the bath agent of Example 6 described later.
And 50.0 g of the bath preparation of Comparative Example 2 at 41 ° C.
Into 180 liters of hot water. Ten test subjects were partially bathed with the right foot in the hot water of Example 5 or 6 and the left foot in the hot water of Comparative Example 2 or 3 three times a day (morning, noon, night) for 5 minutes and 10 days, respectively. Ten days later, the state of the skin sulcus on the skin surface of the forefoot was observed with a magnifying video camera, and scored based on the following criteria. In addition, the evaluation based on the questionnaire was performed according to the following criteria.
【0052】表3に皮膚表面の皮溝状態の評価基準を示
す。Table 3 shows the evaluation criteria for the state of the skin groove on the skin surface.
【0053】[0053]
【表3】 [Table 3]
【0054】表4にアンケート評価方法を示す。Table 4 shows the questionnaire evaluation method.
【0055】[0055]
【表4】 [Table 4]
【0056】入浴効果を調べた結果を表5に示す。Table 5 shows the results of examining the bathing effect.
【0057】[0057]
【表5】 [Table 5]
【0058】表5に記載した通り、メタケイ酸エチルエ
ステル(およびアスコルビン酸リン酸エステル、以下A
sc−Pと略す)を含む入浴剤を用いた場合、比較例と
比べ、皮膚表面の皮溝状態ははっきりしており、アンケ
ート評価においても肌のしっとり感が高かった。As described in Table 5, ethyl metasilicate (and ascorbic acid phosphate, hereinafter A)
In the case where a bath preparation containing sc-P) was used, the state of the crevices on the skin surface was clear and the moist feeling of the skin was high in the questionnaire evaluation as compared with the comparative example.
【0059】実施例1 メタケイ酸エチルエステル14.4mgを、0.1%ポリ
オキシエチレン(20)ラウリルエーテル硫酸ナトリウ
ム水溶液9mlに懸濁させ、精製水で10mlにメスアップ
した。それを、ポアサイズが0.2μm のニトロセルロ
ース膜(アドバンテック東洋製、DISMIC-25 )で濾過滅
菌し、メタケイ酸エチルエステル溶液とした。Example 1 14.4 mg of ethyl metasilicate was suspended in 9 ml of a 0.1% aqueous solution of sodium polyoxyethylene (20) lauryl ether sulfate, and the solution was made up to 10 ml with purified water. It was sterilized by filtration through a nitrocellulose membrane having a pore size of 0.2 μm (manufactured by Advantech Toyo, DISMIC-25) to obtain a metasilicate ethyl ester solution.
【0060】実施例2 ケイ酸メチルエステル20.8mgを用いる以外は、実施
例1と同様にしてケイ酸メチルエステル溶液を調製し
た。Example 2 A silicate methyl ester solution was prepared in the same manner as in Example 1 except that 20.8 mg of silicate methyl ester was used.
【0061】実施例3 メタケイ酸プロピルエステル15.8mg、0.1%ポリ
オキシエチレン(20)ラウリルエーテル硫酸ナトリウ
ム溶液9mlを用いる以外は、実施例1と同様にしてメタ
ケイ酸プロピルエステル溶液を調製した。Example 3 A propyl metasilicate solution was prepared in the same manner as in Example 1 except that 15.8 mg of propyl metasilicate and 9 ml of a 0.1% sodium polyoxyethylene (20) lauryl ether sulfate solution were used. .
【0062】実施例4 オルソケイ酸エチルエステル14.4mgを0.1%ポリ
オキシエチレン(20)ラウリルエーテル硫酸ナトリウ
ム溶液9mlに溶解し、pHを1N水酸化ナトリウムで中和
後、さらにAsc−P10mgを加えて精製水で10mlに
メスアップした。それを、実施例1と同様に濾過滅菌
し、オルソケイ酸エチルエステル溶液を調製した。Example 4 14.4 mg of ethyl orthosilicate was dissolved in 9 ml of 0.1% sodium polyoxyethylene (20) lauryl ether sulfate solution, the pH was neutralized with 1N sodium hydroxide, and 10 mg of Asc-P was further added. In addition, the volume was adjusted to 10 ml with purified water. It was sterilized by filtration in the same manner as in Example 1 to prepare an orthosilicate ethyl ester solution.
【0063】実施例5 下記処方の入浴剤組成物を、粉体を混合する通常の方法
で調製し、メタケイ酸エチルエステル10.00g を含
む入浴剤を100g 作製した。調製時、凝集性を生じな
かった。また45℃、3か月保存しても凝集することは
なかった。Example 5 A bath preparation composition having the following formulation was prepared by a usual method of mixing powder, and 100 g of a bath preparation containing 10.00 g of ethyl metasilicate was prepared. No cohesiveness occurred during preparation. No aggregation occurred even after storage at 45 ° C. for 3 months.
【0064】 メタケイ酸エチルエステル 10.00 g 硫酸ナトリウム 45.00 g 炭酸水素ナトリウム 32.65 g 塩化ナトリウム 5.00 g ポリオキシエチレン(20) 5.00 g ラウリルエーテル硫酸ナトリウム モモの葉エキス 1.30 g 香料 1.00 g 有機色素 0.05 g ────────────────────────────────── 100.00 g Ethyl metasilicate 10.00 g Sodium sulfate 45.00 g Sodium bicarbonate 32.65 g Sodium chloride 5.00 g Polyoxyethylene (20) 5.00 g Sodium lauryl ether sulfate Peach leaf extract 30 g Fragrance 1.00 g Organic dye 0.05 g 10 100.00 g
【0065】実施例6 下記処方の入浴剤組成物を、粉体を混合する通常の方法
で調製し、メタケイ酸エチルエステル15.00g およ
びAsc−P 10.0g を含む入浴剤を100g 作製
した。調製時、凝集性を生じなかった。また45℃、3
か月保存しても凝集することはなかった。Example 6 A bath preparation composition having the following formulation was prepared by a usual method of mixing powder, and 100 g of a bath preparation containing 15.00 g of ethyl metasilicate and 10.0 g of Asc-P were prepared. No cohesiveness occurred during preparation. 45 ° C, 3
There was no aggregation after storage for months.
【0066】 メタケイ酸エチルエステル 15.00 g 硫酸ナトリウム 22.95 g 炭酸水素ナトリウム 46.00 g Asc−P 10.0 g ポリオキシエチレン(20) 5.0 g ラウリルエーテル硫酸ナトリウム 香料 1.0 g 有機色素 0.05 g ────────────────────────────────── 100.00 g Ethyl metasilicate 15.00 g 22.95 g sodium sulfate 46.00 g sodium bicarbonate 10.0 g Asc-P 5.0 g Polyoxyethylene (20) 5.0 g Sodium lauryl ether sulfate 1.0 g Organic dye 0.05 g 10 100.00 g
【0067】比較例1 下記処方の入浴剤組成物を、粉体を混合する通常の方法
で調製し、比較のための入浴剤100g を作製した。Comparative Example 1 A bath preparation composition having the following formulation was prepared by a usual method of mixing powder, and 100 g of a bath preparation for comparison was prepared.
【0068】 硫酸ナトリウム 45.00 g 炭酸水素ナトリウム 42.65 g 塩化ナトリウム 5.00 g ポリオキシエチレン(20) 5.00 g ラウリルエーテル硫酸ナトリウム モモの葉エキス 1.30 g 香料 1.00 g 有機色素 0.05 g ─────────────────────────────────── 100.00 g Sodium sulfate 45.00 g Sodium bicarbonate 42.65 g Sodium chloride 5.00 g Polyoxyethylene (20) 5.00 g Sodium lauryl ether sulfate Peach leaf extract 1.30 g Flavor 1.00 g Organic Dye 0.05 g 10 100.00 g
【0069】比較例2 下記処方の入浴剤組成物を、粉体を混合する通常の方法
で調製し、比較のための入浴剤100g を作製した。Comparative Example 2 A bath preparation composition having the following formulation was prepared by an ordinary method of mixing powder, and 100 g of a bath preparation for comparison was prepared.
【0070】 硫酸ナトリウム 22.95 g 炭酸水素ナトリウム 61.00 g Asc−P 10.0 g ポリオキシエチレン(20) 5.0 g ラウリルエーテル硫酸ナトリウム 香料 1.0 g 有機色素 0.05 g ─────────────────────────────────── 100.00 g Sodium sulfate 22.95 g Sodium bicarbonate 61.00 g Asc-P 10.0 g Polyoxyethylene (20) 5.0 g Sodium lauryl ether sulfate Perfume 1.0 g Organic dye 0.05 g ───────────────────────────────── 100.00 g
【0071】[0071]
【発明の効果】以上の通り、本発明の入浴剤は、老化に
伴うコラーゲンの代謝回転速度低下の改善効果を有し、
ヒト実用試験において、美肌効果に優れ、かつ商品的に
凝集性の無い入浴剤を提供できることは明らかである。As described above, the bath preparation of the present invention has an effect of improving a decrease in collagen turnover rate due to aging,
In a practical human test, it is clear that a bath agent excellent in beautiful skin effect and commercially non-cohesive can be provided.
───────────────────────────────────────────────────── フロントページの続き (58)調査した分野(Int.Cl.7,DB名) A61K 7/00 - 7/50 CA(STN) REGISTRY(STN)────────────────────────────────────────────────── ─── Continued on the front page (58) Field surveyed (Int. Cl. 7 , DB name) A61K 7/ 00-7/50 CA (STN) REGISTRY (STN)
Claims (2)
アルキルエステルを含有することを特徴とする入浴剤。1. A bath additive comprising an alkyl silicate other than an organoalkoxysilane .
アルキルエステルとアスコルビン酸またはその誘導体と
を含有することを特徴とする入浴剤。2. A bath agent comprising an alkyl silicate other than an organoalkoxysilane and ascorbic acid or a derivative thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31256194A JP3272891B2 (en) | 1994-11-22 | 1994-11-22 | Bath additive |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31256194A JP3272891B2 (en) | 1994-11-22 | 1994-11-22 | Bath additive |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08143447A JPH08143447A (en) | 1996-06-04 |
JP3272891B2 true JP3272891B2 (en) | 2002-04-08 |
Family
ID=18030699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP31256194A Expired - Fee Related JP3272891B2 (en) | 1994-11-22 | 1994-11-22 | Bath additive |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3272891B2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10182421A (en) * | 1996-12-27 | 1998-07-07 | Kose Corp | Bath preparation |
US9744193B2 (en) | 2012-09-06 | 2017-08-29 | Orbis Health Solutions Llc | Tumor lysate loaded particles |
AU2013359392C1 (en) | 2012-12-12 | 2016-12-08 | Orbis Health Solutions, Llc | Compositions and methods for tissue regeneration |
CN106456532B (en) | 2014-03-05 | 2020-07-24 | 奥比思健康解决方案有限责任公司 | Vaccine delivery system using yeast cell wall particles |
-
1994
- 1994-11-22 JP JP31256194A patent/JP3272891B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH08143447A (en) | 1996-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4659980B2 (en) | Carbon dioxide-containing viscous composition | |
AU707353B2 (en) | Bioadhesive-wound healing composition | |
CN101474140A (en) | Method for delivering substances to the skin and compositions used therein | |
JPH0446112A (en) | Trichogen | |
EP0822816B1 (en) | Dermatological preparation for treating actinic keratoses | |
JP5106739B2 (en) | Cosmetic compositions and methods | |
JPS61180705A (en) | Cosmetic | |
JP2011088930A (en) | Carbon dioxide percutaneous and transmucosal absorption composition | |
JPH0768114B2 (en) | Bath additive | |
JP3272891B2 (en) | Bath additive | |
HU214945B (en) | Gdermatological and cosmetic composition | |
JP2013163681A (en) | Composition for percutaneous and transmucosal absorption of carbon dioxide | |
JPH06340519A (en) | Collagen metabolism activation agent and cosmetic | |
CA1325774C (en) | Cosmetic preparation incorporating stabilized ascorbic acid | |
JPS5869806A (en) | Cosmetic lotion containing stable collagen | |
JP5164438B2 (en) | Carbon dioxide transdermal / mucosal absorption composition | |
EP1108429A3 (en) | An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases | |
JPH0597697A (en) | Alveolar bone-regenerating agent | |
JP5039704B2 (en) | Moisturizer | |
JP2005022980A (en) | Pack sheet for makeup and method for producing the same | |
JP3277033B2 (en) | Cosmetics | |
JP3187636B2 (en) | Collagen metabolism improver | |
JPH07247210A (en) | Composition for oral cavity | |
JPH0881348A (en) | External preparation for skin | |
RU2096031C1 (en) | Medicinal substance for prophylaxis and treatment of inflammatory diseases of parodontium tissues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080125 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090125 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090125 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100125 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110125 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110125 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120125 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120125 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130125 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130125 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140125 Year of fee payment: 12 |
|
LAPS | Cancellation because of no payment of annual fees |